Research programme: diabetes/obesity therapy - DevgenAlternative Names: Dev 0104
Latest Information Update: 10 Jul 2008
At a glance
- Originator Devgen
- Mechanism of Action Phosphotransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 01 Apr 2004 This programme is still in active development - (BioSquare-2004)
- 10 Jul 2001 Preclinical development for Diabetes and Obesity in Belgium (Unknown route)